Novo-Nordisk

NVO-N

NYSE:NVO

65.86
0.73 (1.10%)
Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries.
More at Wikipedia

Analysis and Opinions about NVO-N

Signal
Opinion
Expert
BUY WEAKNESS
BUY WEAKNESS
February 7, 2020
International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
February 7, 2020
International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.
COMMENT
COMMENT
January 17, 2020
They have good exposure to the diabetes market, though less specialized growth in the next 10 years. They don't own it because their options are not liquid enough.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
January 17, 2020
They have good exposure to the diabetes market, though less specialized growth in the next 10 years. They don't own it because their options are not liquid enough.
BUY
BUY
January 13, 2020
All pharma companies face pricing pressure in a US election year, because US candidates take shots at drug pricing. Also pharma companies need to keep putting new, successful drugs. NN succeeds in putting out new diabetes drugs (they lead this product segment globally).
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
January 13, 2020
All pharma companies face pricing pressure in a US election year, because US candidates take shots at drug pricing. Also pharma companies need to keep putting new, successful drugs. NN succeeds in putting out new diabetes drugs (they lead this product segment globally).
DON'T BUY
DON'T BUY
December 2, 2019
He has avoided it because insulin and products to replace it have had a lot of price increases and he fears they will be looked at by politicians. It is a very defensive issue and should do better when the economy slows.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
December 2, 2019
He has avoided it because insulin and products to replace it have had a lot of price increases and he fears they will be looked at by politicians. It is a very defensive issue and should do better when the economy slows.
TOP PICK
TOP PICK
November 29, 2019
FDA approval for a tablet diabetes drug. China and India will have a growing market for this as well. The trend will help the bottom line and profitability. He's owned it since 1997, and though it hasn't done much in the last 5 years, it is picking up. They are also completely off the grid and is very environmental. (Analysts’ price target is $62.73)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 29, 2019
FDA approval for a tablet diabetes drug. China and India will have a growing market for this as well. The trend will help the bottom line and profitability. He's owned it since 1997, and though it hasn't done much in the last 5 years, it is picking up. They are also completely off the grid and is very environmental. (Analysts’ price target is $62.73)
BUY WEAKNESS
BUY WEAKNESS
November 5, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 5, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

TOP PICK
TOP PICK
September 26, 2019
Their business is in hemophilia and diabetes (450 million have it globally and the number will rise). They make an obesity drug (a pill, that's showing growth) and sell the most insulin in the world. (Analysts’ price target is $56.45)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
September 26, 2019
Their business is in hemophilia and diabetes (450 million have it globally and the number will rise). They make an obesity drug (a pill, that's showing growth) and sell the most insulin in the world. (Analysts’ price target is $56.45)
TOP PICK
TOP PICK
August 15, 2019
Big franchise is in diabetes. Explosive, secular growth in diabetes, and NVO is the largest producer of insulin in the world. Plus biopharma business. Yield is 1.77%. (Analysts’ price target is $54.45)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 15, 2019
Big franchise is in diabetes. Explosive, secular growth in diabetes, and NVO is the largest producer of insulin in the world. Plus biopharma business. Yield is 1.77%. (Analysts’ price target is $54.45)
BUY
BUY
August 2, 2019
Over the next 25 years, type 2 diabetes will grow 55% led by India and China. Demand will be there. Novo needs to go and get this market. Starting to show better revenues and operating margins. They also have a new drug that is not just for diabetes but for weight loss.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 2, 2019
Over the next 25 years, type 2 diabetes will grow 55% led by India and China. Demand will be there. Novo needs to go and get this market. Starting to show better revenues and operating margins. They also have a new drug that is not just for diabetes but for weight loss.
HOLD
HOLD
June 21, 2019
About to come out with a pill instead of injections. Stock has popped recently. Type 2 diabetics are going to increase 50% in the next 2 years, mainly in India and China. Margins are being squeezed. Have to work harder to get sales. Likes what they're doing. Leaders in the industry.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
June 21, 2019
About to come out with a pill instead of injections. Stock has popped recently. Type 2 diabetics are going to increase 50% in the next 2 years, mainly in India and China. Margins are being squeezed. Have to work harder to get sales. Likes what they're doing. Leaders in the industry.
TOP PICK
TOP PICK
April 24, 2019
The play is the growth in diabetes -- 11% per year. More drugs and medications will be required and this company has the best market share in the space. As this is a global issue, they worldwide coverage is a great advantage. Yield 3.2% (Analysts’ price target is $53.45)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
April 24, 2019
The play is the growth in diabetes -- 11% per year. More drugs and medications will be required and this company has the best market share in the space. As this is a global issue, they worldwide coverage is a great advantage. Yield 3.2% (Analysts’ price target is $53.45)
HOLD
HOLD
February 15, 2019
The company understands that diabetes is growing in China and India. They've been raising market share there. International operations grew by 7%. Oral pills instead of insulin shots are coming out shortly. Increased dividend, a bit below average. Oral pills, if positive, could easily be a 1-5B blockbuster.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
February 15, 2019
The company understands that diabetes is growing in China and India. They've been raising market share there. International operations grew by 7%. Oral pills instead of insulin shots are coming out shortly. Increased dividend, a bit below average. Oral pills, if positive, could easily be a 1-5B blockbuster.
TOP PICK
TOP PICK
December 13, 2018
Given that markets will be lack luster he is looking for defensive names. They are focused on the diabetes space. The disease is growing at double digit rates. With their economies of scale, their profit margin is higher than their competitors. The most significant growth in diabetes is in emerging markets where they pay for the drugs themselves. They have to be able to reduce their prices in these markets. (Analysts’ price target is $49.60)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
December 13, 2018
Given that markets will be lack luster he is looking for defensive names. They are focused on the diabetes space. The disease is growing at double digit rates. With their economies of scale, their profit margin is higher than their competitors. The most significant growth in diabetes is in emerging markets where they pay for the drugs themselves. They have to be able to reduce their prices in these markets. (Analysts’ price target is $49.60)
BUY
BUY
November 8, 2018
Biggest growth is on diabetes. Market leader. The numbers were a little soft on the last report. Structural growth story. (Analysts’ price target is $45.85)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 8, 2018
Biggest growth is on diabetes. Market leader. The numbers were a little soft on the last report. Structural growth story. (Analysts’ price target is $45.85)
PAST TOP PICK
PAST TOP PICK
November 2, 2018

(A Top Pick Oct 04/17, Down 7%) Has owned this for 22 years. #1 insulin maker in the world. Just came out with a drug for weight loss. There'll be a 54% increase in diabetes in 12 years. They and Merck had the best revenue growth. Stock fell a little because a competitor got FDA approval for a similar insulin. They are selling more outside the U.S. and need to sell more to China and India. Then, the street will favour them again.

Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 2, 2018

(A Top Pick Oct 04/17, Down 7%) Has owned this for 22 years. #1 insulin maker in the world. Just came out with a drug for weight loss. There'll be a 54% increase in diabetes in 12 years. They and Merck had the best revenue growth. Stock fell a little because a competitor got FDA approval for a similar insulin. They are selling more outside the U.S. and need to sell more to China and India. Then, the street will favour them again.

Showing 1 to 15 of 83 entries

Novo-Nordisk(NVO-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 5

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 5 stock analysts published opinions about NVO-N. 4 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY on WEAKNESS. Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by David Driscoll on 2020-02-07. Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

5 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2020-07-16, Novo-Nordisk (NVO-N) stock closed at a price of $65.86.